Oct. 30 at 10:31 PM
$GLPG has new board members: Neil Johnston, a former global head of BD and licensing at Novartis and Devang Bhuva, SVP of CD and alliances at Gilead as its new representative. This is a welcome development but I'd rather see someone like Johnston taking over as CEO. Stoffels was not active enough but he had a vision. The new leadership has nothing: we're going to do a spin-out, we're going to sell cell therapy, we are going to shut it down but maybe still sell... And no vision about new deals not to mention actual deals. This has to change or they have to wind down entirely and return cash to shareholders.
